15.90
-3.64%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zelluna A
Its shares trade on Oslo Børs under the ticker ZLNA.OL. It has been listed since 3 June 2019. In the fiscal year to 31 December 2024, it reported revenue of NOK 53,000 and a net loss of NOK 105.2m. At that date it held total assets of NOK 50.4m and shareholders' equity of NOK 36.0m.
Ultimovacs AS is a pharmaceutical company, which engages in the development of novel immunotherapies against cancer. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The firm is performing a broad clinical development program with clinical trials in Europe and the USA.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Jun 2019
- Employees
- 19
- Website
- ultimovacs.com ↗
Leadership
Pay as last reported
- Mr. Anders TuvChairman of the Board, since 2025
- Mr. Hans EidInterim Chief Executive Officer, Chief Financial Officer, since 2024NOK 3.3m
- Mr. Audun TornesChief Technology OfficerNOK 2.1m
- Mr. Ton BerkienChief Business OfficerNOK 267,000
- Mr. Jens BjorheimChief Medical OfficerNOK 2.7m
- Ms. Orla CallionHead of Regulatory Affairs & QA
- Mr. Oivind FossHead of Clinical OperationsNOK 2.0m
- Ms. Gudrun TroiteHead of Project CoordinationNOK 1.9m
- Ms. Ingunn WestgaardHead of ResearchNOK 1.8m
- Ms. Anne WorsoeHead of Investor Relations & Communication
- Mrs. Eva-Lotta Allan CoulterDirector
- Ms. Charlotte Berg-SvendsenDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zelluna ASA has a lead product candidate UV1, a peptide-based vaccine targeting telomerase for cancer immunotherapy.
- The company operates with a focused clinical development program in Europe and the USA for its UV1 product.
- Zelluna ASA's headquarters in Oslo, Norway, supports its biotechnology sector operations within the Health Care industry.
Weaknesses
- Zelluna ASA has only 19 employees, indicating a small operational scale.
- The company's sole product line UV1 is currently in clinical development without commercialization.
- Zelluna ASA's IPO occurred in 2019, indicating limited market history for the company.
Opportunities
- Zelluna ASA can expand its clinical trials in Europe and the USA to accelerate UV1's development.
- The biotechnology sector in Norway offers potential for growth within the Health Care industry.
- The company's platform for UV1 could be leveraged for combination therapies with other immuno-oncology drugs.
Threats
- Zelluna ASA faces competition in the biotechnology sector for cancer immunotherapies.
- The clinical development of UV1 may encounter delays or failures in Europe and the USA trials.
- The company's small employee count of 19 may limit its ability to manage regulatory challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.